Joan S Brugge

List of Publications by Year
in descending order

53	4,150	159585	182427
papers	citations	30 h-index	51 g-index

59	59	59	7981
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Signal Transduction in Cancer. Cold Spring Harbor Perspectives in Medicine, 2015, 5, a006098-a006098.	6.2	665
2	Oncogene-like induction of cellular invasion from centrosome amplification. Nature, 2014, 510, 167-171.	27.8	360
3	Cycling cancer persister cells arise from lineages with distinct programs. Nature, 2021, 596, 576-582.	27.8	236
4	A New Mutational aktivation in the PI3K Pathway. Cancer Cell, 2007, 12, 104-107.	16.8	230
5	Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells. Cell Metabolism, 2016, 23, 867-880.	16.2	214
6	Cancer Cells Co-opt the Neuronal Redox-Sensing Channel TRPA1 to Promote Oxidative-Stress Tolerance. Cancer Cell, 2018, 33, 985-1003.e7.	16.8	184
7	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers. Science Translational Medicine, 2017, 9, .	12.4	174
8	Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nature Communications, 2015, 6, 7419.	12.8	149
9	Organoid cultures from normal and cancer-prone human breast tissues preserve complex epithelial lineages. Nature Communications, 2020, 11, 1711.	12.8	134
10	Deubiquitinases Maintain Protein Homeostasis and Survival of Cancer Cells upon Glutathione Depletion. Cell Metabolism, 2019, 29, 1166-1181.e6.	16.2	121
11	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell, 2020, 78, 1096-1113.e8.	9.7	114
12	3D Culture Models with CRISPR Screens Reveal Hyperactive NRF2 as a Prerequisite for Spheroid Formation via Regulation of Proliferation and Ferroptosis. Molecular Cell, 2020, 80, 828-844.e6.	9.7	110
13	Mesenchymal gene programâ€“expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. Journal of Clinical Investigation, 2014, 124, 2611-2625.	8.2	110
14	Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer. Nature Reviews Cancer, 2022, 22, 323-339.	28.4	107
15	Mapping the dynamics of force transduction at cellâ€“cell junctions of epithelial clusters. ELife, 2014, 3, e03282.	6.0	99
16	Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nature Protocols, 2021, 16, 1936-1965.	12.0	97
17	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clinical Cancer Research, 2017, 23, 1263-1273.	7.0	95
18	Starved epithelial cells uptake extracellular matrix for survival. Nature Communications, 2017, 8, 13989.	12.8	91

#	Article	IF	Citations
19	Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing. Cell Reports, 2020, 33, 108566.	6.4	75
20	Akt regulation of glycolysis mediates bioenergetic stability in epithelial cells. ELife, 2017, 6, .	6.0	55
21	Cytokinesis involves a nontranscriptional function of the Hippo pathway effector YAP. Science Signaling, 2016, 9, ra23.	3.6	53
22	ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP. Cancer Research, 2016, 76, 7168-7180.	0.9	53
23	The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expressionâ€“Based Meta-Analysis. Clinical Cancer Research, 2016, 22, 6039-6050.	7.0	48
24	The enemy of my enemy is my friend. Nature, 2015, 527, 170-171.	27.8	47
25	Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition. JCI Insight, 2016, 1, .	5.0	45
26	Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nature Communications, 2017, 8, 365.	12.8	44
27	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nature Communications, 2020, 11, 5824.	12.8	42
28	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	16.8	40
29	Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patientâ€“Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Molecular Cancer Therapeutics, 2019, 18, 642-655.	4.1	39
30	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	4.1	39
31	In vitro Mesothelial Clearance Assay that Models the Early Steps of Ovarian Cancer Metastasis. Journal of Visualized Experiments, 2012, , .	0.3	36
32	Role for polo-like kinase 4 in mediation of cytokinesis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11309-11318.	7.1	30
33	Transient commensal clonal interactions can drive tumor metastasis. Nature Communications, 2020, 11, 5799.	12.8	30
34	Casting light on focal adhesions. Nature Genetics, 1998, 19, 309-311.	21.4	25
35	Fibroblastâ€“tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16500-16508.	7.1	23
36	Identification of cancer genes that are independent of dominant proliferation and lineage programs. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E11276-E11284.	7.1	20

#	Article	IF	Citations
37	Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo. Molecular Cancer Therapeutics, 2019, 18, 1115-1126.	4.1	20
38	Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Research, 2020, 22, 132.	5.0	19
39	Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo. Npj Breast Cancer, 2017, 3, 18.	5.2	18
40	Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics. Science Signaling, 2021, 14, .	3.6	10
41	Clinical evaluation of BCL-2/XL levels pre- and post- HER2-targeted therapy. PLoS ONE, 2021, 16, e0251163.	2.5	9
42	Metabolic changes promote rejection of oncogenic cells. Nature Cell Biology, 2017, 19, 414-415.	10.3	6
43	Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts. Oncogene, 2022, 41, 112-124.	5.9	6
44	Into the deep: Refocusing on 3D. Nature Cell Biology, 2012, 14, 332-332.	10.3	5
45	Coping with the metabolic stress of leaving home. Cell Research, 2016, 26, 757-758.	12.0	5
46	The myosin-II-responsive focal adhesion proteome: a tour de force?. Nature Cell Biology, 2011, 13, 344-346.	10.3	4
47	Not just Salk. Science, 2017, 357, 1105-1106.	12.6	4
48	CRB3 and the FERM protein EPB41L4B regulate proliferation of mammary epithelial cells through the release of amphiregulin. PLoS ONE, 2018, 13, e0207470.	2.5	3
49	United They Stand, Divided They Fall. Cell Metabolism, 2019, 30, 624-625.	16.2	3
50	Meta-analysis of breast cancer expression data using published gene signatures to reveal key cellular processes implicated in chemosensitivity and resistance.. Journal of Clinical Oncology, 2015, 33, 509-509.	1.6	1
51	Moving Closer To Victory. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 281-288.	1.1	0
52	Characterization of Mammary Cells Coâ€expressing Separate Lineage Markers. FASEB Journal, 2020, 34, 1-1.	0.5	0
53	Abstract P5-01-02: Single cell RNA transcriptomics reveals tumor promoting mammary cell subpopulation upon replication stress in BRCA1 mutant breast cancer mouse model. Cancer Research, 2022, 82, P5-01-02-P5-01-02.	0.9	0